Allogene Therapeutics, Inc. Common Stock

Day range

$1.22 – $1.33

Open

$1.32

Prev close

$1.25

Volume

8.3M

Market cap

$431.86M

Shares out

345.49M

P/E

—

P/S

93.07

P/B

0.99

P/FCF

—

ROE

-37.9%

ROA

-30.1%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 22, 2026

• Executive leadershipSep 2, 2026

  On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the "Company"), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.

• Earnings and performanceAug 12, 2026

  On August 12, 2026, Allogene Therapeutics, Inc. (the "Company") provided a corporate update and announced its financial results for the quarter ended June 30, 2026 in the press release attached hereto as Exhibit 99.1

• Executive leadershipMay 28, 2026

  Dr. Chang's last day of service in these positions will be June 30, 2026. In connection with the conclusion of his service as the Company's President and Chief Executive Officer, Dr. Chang will be eligible for certain severance benefits under the terms of the Company's Change in Control and Severance Benefit Plan.

• Deal agreementsMay 13, 2026

  The License Agreement granted the Overland Parties an exclusive license to develop, manufacture and commercialize certain allogeneic CAR T cell therapies directed at four targets, BCMA, CD70, FLT3 and DLL3 in greater China, Taiwan, South Korea and Singapore. Under the License Agreement, the Company received an upfront payment $40.0 million and non-cash consideration of $79.0 million in the form of shares of series seed preferred stock of Overland and was entitled to additional regulatory milestone payments of up to $40.0 million, if achieved, and a flat mid single-digit royalty on net sales in the licensed territory.

• Equity activityApr 15, 2026

  On April 14, 2026, we entered into an underwriting agreement with Goldman Sachs & Co. LLC, Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein, relating to the issuance and sale in a public offering of 87,500,000 shares of our common stock, par value $0.001 per share. The price to the public in the offering is $2.00 per share. The gross proceeds to us from the offering are expected to be approximately $175.0 million.

Days to cover

9.0

Short interest

55.61M

Avg volume

6.18M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
  neutralGlobeNewswire Inc.· Apr 14, 2026
• Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
  positiveBenzinga· Dec 16, 2025
• Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
  positiveGlobeNewswire Inc.· Dec 15, 2025
• U.S. CAR T-Cell Therapies Market Grows at 30.4% CAGR, Soars USD 42.61 Billion by 2035
  positiveGlobeNewswire Inc.· Nov 27, 2025
• High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
  positiveBenzinga· Jul 23, 2025